ARTICLE | Clinical News
Ameluz regulatory update
December 30, 2016 1:46 AM UTC
EMA’s CHMP recommended approval of an expanded label for Biofrontera’s Ameluz aminolevulinic acid to include treatment of superficial and/or nodular basal cell carcinoma (BCC) unsuitable for surgical ...
BCIQ Company Profiles